Efemoral Medical announced the presentation of long-term results from the initial 20 patients enrolled across four sites in ...

A case study on intravascular lithotripsy for the treatment of calcified carotid disease to demonstrate technical feasibility ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated ...

Candesartan treatment tended to improve the prognostic benefits after femoral artery stent implantation, suggesting that an antiproliferative effect after stenting may need higher doses than an ...

The following is a summary of "Impact of Peripheral Arterial Disease on Clinical Outcomes of Patients Undergoing Complex vs ...

0.41 ± 1.0 mm late lumen loss at 6 months (angiographic subset, n=10) 4.74 ± 0.86 mm mean minimal lumen diameter at 6 months (angiographic subset, n=10) "In this first patient experience, I ...

A new Intermountain Health study finds that peripheral artery disease, a condition that affects more than 10 million Americans over the age of 40, is often underdiagnosed and undertreated ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. (HealthDay News) — For patients with symptomatic peripheral ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Ozempic improved walking distance in patients with diabetes and peripheral artery disease at 1 year. An exploratory analysis suggested Ozempic reduced risk for major limb events and mortality.